Welcome to our dedicated page for Entero Therapeutics SEC filings (Ticker: ENTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Entero Therapeutics, Inc. (NASDAQ: ENTO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including Forms 10-K, 10-Q, 8-K, registration statements, and other required reports. These documents provide detailed information on Entero’s dual focus: late clinical-stage development of targeted, non-systemic therapies for gastrointestinal diseases and the integration of Grid AI, a grid-edge, AI-driven software and device platform.
In its S-1/A registration statement, Entero outlines its GI pipeline and describes Adrulipase as a recombinant lipase enzyme for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. The same filing explains that the company is a smaller reporting company with common stock listed on the Nasdaq Capital Market under the symbol ENTO. Investors can use annual reports on Form 10-K and quarterly reports on Form 10-Q, when filed, to review research and development activities, risk factors, and financial statements.
Recent Forms 8-K are particularly important for understanding Entero’s corporate transition. One 8-K details the share exchange agreement through which Entero acquired 100% of Grid AI Corp, issuing common and Series H non-voting convertible preferred stock and granting Grid AI shareholders the right, subject to conditions, to designate a majority of directors. Other 8-K filings describe Nasdaq correspondence regarding compliance with Listing Rule 5550(b)(1), a Securities Purchase Agreement for a promissory note and warrant financing, and governance arrangements related to Grid AI’s shareholders and board representation.
A Form 12b-25 (NT 10-Q) explains that Entero requested additional time to file a quarterly report due to the complexity of accounting for the Grid AI acquisition. Together, these filings allow investors to track equity structure, financing arrangements, listing compliance, and the accounting treatment of major transactions. On Stock Titan, AI-powered tools summarize lengthy documents such as 10-Ks, 10-Qs, and 8-Ks, highlight key terms in registration statements like the S-1/A, and help surface notable items in ownership and governance disclosures, so readers can more quickly interpret ENTO’s regulatory history and ongoing obligations.
GridAI Technologies Corp. submitted a Form 12b-25 notification stating it could not timely file its Form 10-K for the year ended December 31, 2025 while it reviews accounting treatment and related disclosures for its recent acquisition of GridAI Corp. The company expects to file the 10-K no later than the fifteenth calendar day following the prescribed due date. The notification, signed by Anna Skowron, Interim Chief Financial Officer, indicates that other periodic reports for the prior 12 months have been filed and that no significant change in results of operations is anticipated to appear in the delayed report.
GridAI Technologies Corp. received a Schedule 13G/A filing from Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation reporting a passive ownership position. The reporting persons beneficially own 31,000 shares of common stock, representing 0.92% of the class as of 12/31/2025.
Renaissance reports sole voting and dispositive power over these shares and confirms they are held in the ordinary course of business, not for the purpose of changing or influencing control of GridAI. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds from these securities.
GridAI Technologies Corp. received a new Schedule 13G disclosure showing that Strategic EP, LLC and Alexander Chase Deitch together report beneficial ownership of 209,541 shares of common stock, representing 5.0% of the company’s outstanding shares. This percentage is based on 4,162,695 shares outstanding as of the date of the statement. The filing states the investors share voting and dispositive power over these shares and classify themselves as passive holders, certifying that the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control. They also hold warrants and pre-funded warrants subject to 4.99% or 9.99% beneficial ownership limits, so the underlying shares are excluded from the reported ownership.
GridAI Technologies Corp. director Edward Borkowski reported a stock grant. On January 1, 2026, he was awarded 40,000 restricted stock units that will be settled in shares of common stock with a par value of $0.0001 per share. The filing states these restricted stock units vested immediately upon issuance on January 1, 2026. Following this grant, Borkowski beneficially owns 60,248 shares of common stock directly.
GridAI Technologies Corp. completed a previously agreed rescission transaction involving ImmunogenX, LLC on December 31, 2025. Under this deal, the company transferred to the former ImmunogenX, Inc. shareholders all of the membership interests of ImmunogenX, LLC that it held, so ImmunogenX, LLC is no longer a subsidiary and the company no longer owns any interest in it.
The company notes that this disposition is considered a significant asset sale for reporting purposes, and it has filed unaudited pro forma consolidated financial statements as an exhibit to show how the transaction would have affected its historical financials.
Entero Therapeutics, Inc. reported a Q3 2025 net loss of $1,152,809, improving from $2,580,971 a year earlier as operating expenses declined. For the first nine months of 2025, net loss narrowed to $3,410,700 from $5,821,067 in the prior-year period. Cash and cash equivalents were $2,517,218 at September 30, 2025, with an accumulated deficit of $205,798,707, and management states there is substantial doubt about the company’s ability to continue as a going concern.
Total assets rose to $135,370,340 from $85,409,506, driven by the March 2024 ImmunogenX acquisition and the September 30, 2025 acquisition of Grid AI Corp., which added developed technology, customer relationships, trade name intangibles and $25,796,163 of goodwill. Assets and liabilities related to ImmunogenX, including Latiglutenase and CypCel, are classified as held for sale and treated as discontinued operations. The Grid AI deal also introduced a non-controlling interest of $5,287,000 and new Series H preferred stock that is convertible into common shares subject to shareholder approval.
Entero Therapeutics, Inc. filed a Form 12b-25 to notify that its Form 10-Q for the quarter ended September 30, 2025 will be filed late. The company is still reviewing the accounting treatment of its acquisition of GridAI Corp. and needs more time to ensure the financial statements comply with applicable accounting standards. Under Rule 12b-25, Entero expects to file the quarterly report no later than the fifth calendar day after the original due date.
Entero Therapeutics (ENTO) reported that on October 17, 2025, the stockholders of GridAI Corp waived their right to appoint two directors to Entero’s Board as provided in Section 5.09 of the Share Exchange Agreement dated September 30, 2025. The waiver remains in effect until Entero’s shareholders approve the appointment of such directors at a duly called meeting in accordance with applicable laws.
This update follows the previously disclosed agreement referenced in the company’s October 6, 2025 filing and reflects a governance step that defers board appointments pending shareholder approval.
Entero Therapeutics (ENTO) reported that Nasdaq has confirmed the company is back in compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1). Compliance was affirmed in a letter dated October 28, 2025, following Entero’s October 6 disclosure tied to a September 30 share exchange with GridAI.
The company had previously fallen out of compliance after reporting stockholders’ equity of ($3,876,738) as of December 31, 2024, below the $2.5 million minimum. Nasdaq had granted an extension through October 8, 2025, to regain compliance. Nasdaq cautioned that if Entero does not evidence compliance in its next periodic report, the company may face delisting, with the option to appeal to a Hearings Panel.